¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

(¿Â¶óÀÎ) Á¦47Â÷ ´ëÇѾÏÇÐȸ Çмú´ëȸ ¹× Á¦7Â÷ ±¹Á¦¾ÏÄÁÆÛ·±½º 1 : 2021-06-17

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
(¿Â¶óÀÎ) Á¦47Â÷ ´ëÇѾÏÇÐȸ Çмú´ëȸ ¹× Á¦7Â÷ ±¹Á¦¾ÏÄÁÆÛ·±½º 1 : 2021-06-17
±³À°ÀÏÀÚ : 2021-06-17
±³À°Àå¼Ò : ¿Â¶óÀÎ ±³À°(½Ç½Ã°£ È­»ó °­ÀÇ)  
±³À°ÁÖÁ¦ : (¿Â¶óÀÎ) Á¦47Â÷ ´ëÇѾÏÇÐȸ Çмú´ëȸ ¹× Á¦7Â÷ ±¹Á¦¾ÏÄÁÆÛ·±½º 1 
ÁÖÃÖ±â°ü : ´ëÇѾÏÇÐȸ
´ã´çÀÚ : ÀÌÈñ¿¬
¿¬¶ôó : 02-792-1486  
À̸ÞÀÏ : cancer2@kams.or.kr      
±³À°Á¾·ù : ³»°ú, ¿Ü°ú, ¼Ò¾Æû¼Ò³â°ú, »êºÎÀΰú, Á¤Çü¿Ü°ú, ½Å°æ¿Ü°ú, ÈäºÎ¿Ü°ú, ¼ºÇü¿Ü°ú, ¾È°ú, À̺ñÀÎÈÄ°ú, ÇǺΰú, ºñ´¢ÀÇÇаú, ¿µ»óÀÇÇаú, ¹æ»ç¼±Á¾¾çÇаú, ¸¶ÃëÅëÁõÀÇÇаú, ½Å°æ°ú, ÀçÈ°ÀÇÇаú, °áÇÙ°ú, Áø´Ü°Ë»çÀÇÇаú, º´¸®°ú, °¡Á¤ÀÇÇаú, ÇÙÀÇÇаú, ÀÀ±ÞÀÇÇаú¿¹¹æÀÇÇÐ, ÇغÎÇÐ, »ý¸®ÇÐ, »ýÈ­ÇÐ, ºÐÀÚ»ý¹°ÇÐ, ¹Ì»ý¹°ÇÐ, ¾à¸®ÇÐ
Âü¼®¿¹»óÀοø : 900¸í
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 18 ½Ã°£ 10ºÐ  
¼¼ºÎ¼ö°­·á : 90,000¿ø      
ºñ°í 1. ȸ¿ø: 1) ±³¼ö, Àü¹®ÀÇ, ¼±ÀÓ¿¬±¸¿ø: 6¸¸¿ø / 2) Àü°øÀÇ, ¿¬±¸¿ø, ´ëÇпø»ý: 3¸¸¿ø / 3) ¾÷ü ¹× ¾÷ü¿¬±¸¼Ò: 6¸¸¿ø 2. ºñȸ¿ø: 1) ±³¼ö, Àü¹®ÀÇ, ¼±ÀÓ¿¬±¸¿ø: 9¸¸¿ø / 2) Àü°øÀÇ, ¿¬±¸¿ø, ´ëÇпø»ý: 4¸¸¿ø / 3) ¾÷ü ¹× ¾÷ü¿¬±¸¼Ò: 9¸¸¿ø      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 06-17 Room C 08:30~08:50 Transforming therapeutic strategy from advanced to early stage EGFR-mutation positive NSCLC  ±èŹÎ(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 06-17 Room C 08:50~09:10 Recent update of CheckMate 9LA and CheckMate 227 pivotal trials in 1L NSCLC  ÀÓ¼±¹Î(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 06-17 Room C 09:10~09:30 A new 3G EGFR TKI, lazertinib: It  Á¶º´Ã¶(¿¬¼¼ÀÇ´ë) 
È޽Ġ06-17  09:30~09:40 È޽Ġ () 
±³À°½Ã°£ 06-17 Room A 09:40~10:20 Vaccines for cancer prevention and treatment  Mary L. (Nora) Disis(University of Washington) 
È޽Ġ06-17  10:20~10:30 È޽Ġ () 
±³À°½Ã°£ 06-17 Room A 10:30~10:55 Single-cell epigenomics  Céline Vallot(Institut Curie) 
±³À°½Ã°£ 06-17 Room A 10:55~11:20 Global epigenetic landscape  Anders Lindroth(±¹¸³¾Ï¼¾ÅÍ) 
±³À°½Ã°£ 06-17 Room A 11:20~11:45 Epigenetic therapy  Toshikazu Ushijima(National Cancer Center Research Institute) 
±³À°½Ã°£ 06-17 Room A 11:45~12:10 Epigenetic markers in immunotherapy  ÃÖÁ¤±Õ(KAIST) 
±³À°½Ã°£ 06-17 Room B 10:30~10:55 Development of ctDNA assay and future perspective  ¹æµÎÈñ(¿¬¼¼´ë) 
±³À°½Ã°£ 06-17 Room B 10:55~11:20 ctDNA testing methods and data analysis algorithm  ÀÌ¿ìâ(¿ï»êÀÇ´ë) 
±³À°½Ã°£ 06-17 Room B 11:20~11:45 Clinical application of ctDNA in surgical field  ÇÑ¿ø½Ä(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 06-17 Room B 11:45~12:10 AI based cancer screening and MRD detection using cfDNA-WGS  Á¶ÀºÇØ(³ì½ÊÀÚ Áö³ð) 
±³À°½Ã°£ 06-17 Room C 10:30~10:55 Benefit and risk of surgical treatment of spinal metastasis  Naresh Kumar(National University Hospital) 
±³À°½Ã°£ 06-17 Room C 10:55~11:20 Radiotherapy for spinal metastasis: Benefit and risk or stereotatic radiotherapy for spinal metastasis  ±è¼ö»ê(¿ï»êÀÇ´ë) 
±³À°½Ã°£ 06-17 Room C 11:20~11:45 RANKL as a therapeutic target for bone metastasis  Kazuo Okamoto(University of Tokyo) 
±³À°½Ã°£ 06-17 Room C 11:45~12:10 Bone-targeted agents in metastatic bone tumors  ¾ÈÁøÈñ(¿ï»êÀÇ´ë) 
½Ä»ç 06-17  12:10~12:50 ½Ä»ç  () 
±³À°½Ã°£ 06-17 Room A 12:50~13:20 Overview of CDK4/6 inhibitors: From past to future  ÀÌ°æÈÆ(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 06-17 Room B 12:50~13:20 Optimal combination therapy with pembrolizumab and TKIs for mRCC  ±èÂù(Â÷ÀÇ´ë) 
±³À°½Ã°£ 06-17 Room C 12:50~13:20 Current practice and new approaches with oxaliplatin in GI cancers  ÀüÈ«Àç(Â÷ÀÇ´ë) 
È޽Ġ06-17  13:20~13:30 È޽Ġ () 
±³À°½Ã°£ 06-17 Room A 13:30~13:55 Targeting DDR pathways in cancer treatment and selection of the right patients  ÀÓ¼®¾Æ(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 06-17 Room A 13:55~14:20 Clinical evidence of PARP inhibitors: Focusing on breast and ovarian cancer  Á¤°æÇØ(¿ï»êÀÇ´ë) 
±³À°½Ã°£ 06-17 Room A 14:20~14:45 DDR in immunotherapy and radiotherapy  Robert Samstein(Icahn School of Medicine at Mount Sinai) 
±³À°½Ã°£ 06-17 Room A 14:45~15:10 New DDR inhibitors and novel strategies for targeting DDR in cancer  Timothy A. Yap(MD Anderson Cancer Center) 
±³À°½Ã°£ 06-17 Room B 13:30~13:55 Lung cancer surgery  ¹Ú¼º¿ë(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 06-17 Room B 13:55~14:20 Breast cancer surgery  ÀÌÁØ¿ì(ÀÌ´ë¸ñµ¿º´¿ø) 
±³À°½Ã°£ 06-17 Room B 14:20~14:45 Gastric cancer surgery  ·ù±Ù¿ø(±¹¸³¾Ï¼¾ÅÍ) 
±³À°½Ã°£ 06-17 Room B 14:45~15:10 Melanoma surgery  Sandra L. Wong(Dartmouth-Hitchcock Medical Center) 
±³À°½Ã°£ 06-17 Room C 13:30~13:55 Lessons from NCI-COG Pediatric MATCH trial for pediatric precision medicine  Donald Williams Parsons(Baylor College of Medicine Texas Children) 
±³À°½Ã°£ 06-17 Room C 13:55~14:20 Role of immunotherapy for sarcomas  ¹ÚÁ¤¾Æ(Memorial Sloan-Kettering Cancer Center) 
±³À°½Ã°£ 06-17 Room C 14:20~14:45 Molecular profiling of CNS tumors  ¿øÀç°æ(¼­¿ï´ëº´¿ø) 
±³À°½Ã°£ 06-17 Room C 14:45~15:10 Recent advances in CAR-T therapy  °­ÇüÁø(¼­¿ïÀÇ´ë) 
È޽Ġ06-17  15:10~15:20 È޽Ġ () 
±³À°½Ã°£ 06-17 Room A 15:20~15:45 Proteogenomic landscape of lung adenocarcinoma and its therapeutic targets  Michael A. Gillette(Broad Institute of MIT and Harvard) 
±³À°½Ã°£ 06-17 Room A 15:45~16:10 Proteogenomic characterization of gastric cancer  È²´ëÈñ(¼­¿ï´ë) 
±³À°½Ã°£ 06-17 Room A 16:10~16:35 Proteogenomic landscape of clear cell renal cell carcinoma  Hui Zhang(Johns Hopkins University) 
±³À°½Ã°£ 06-17 Room A 16:35~17:00 Pharmaco-proteogenomics of glioblastoma  ±èÇö¼®(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 06-17 Room B 15:20~15:45 Hypofractionated RT for breast cancer: From months to a week  ±èÁØ¿ø(°­³²¼¼ºê¶õ½ºº´¿ø) 
±³À°½Ã°£ 06-17 Room B 15:45~16:10 Optimized fractionation scheme of radiation therapy for hepatobiliary and pancreatic cancer  ÁöÀDZÔ(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 06-17 Room B 16:10~16:35 SBRT and hypofractionated RT for early stage lung cancer  ³ëÀç¸í(¼º±Õ°üÀÇ´ë) 
±³À°½Ã°£ 06-17 Room B 16:35~17:00 Pros and cons of hypofractionated RT to bone and brain metastasis  ±è±Ôº¸(ÀÌÈ­ÀÇ´ë) 
±³À°½Ã°£ 06-17 Room C 15:20~15:45 Investigation on improving bioinformatic markers of cancer immunotherapy response by radio-chemotherapy  ±è½Å(°è¸íÀÇ´ë) 
±³À°½Ã°£ 06-17 Room C 15:45~16:10 Multidisciplinary approach in young women with breast cancer  ±èÈñÁ¤(¿ï»êÀÇ´ë) 
±³À°½Ã°£ 06-17 Room C 16:10~16:35 Heterogeneity in tumor-infiltrating lymphocytes: Individualized strategy according to the tumor specificity  ÀÓ°¡¶÷(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 06-17 Room C 16:35~17:00 Scientific validation and clinical application of lung cancer organoid  Á¤Àç¿í(Ãæ³²ÀÇ´ë) 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" (¿Â¶óÀÎ) Á¦47Â÷ ´ëÇѾÏÇÐȸ Çмú´ëȸ ¹× Á¦7Â÷ ±¹Á¦¾ÏÄÁÆÛ·±½º 1 : 2021-06-17""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û ¼¼ºê¶õ½ºº´¿ø (¿Â¶óÀÎ) ¾È°ú ±Ý¿äÁý´ãȸ(OCT angiography in glaucoma) : 2021-06-18
´ÙÀ½±Û 150ȸ ÇѸ²´ëÇб³Ãáõ¼º½Éº´¿ø ¼ÒÈ­±â¼¾ÅÍ ¿¬¼ö±³À° : 2021-06-16
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20664 ¼­¿ï °­³²¼¼ºê¶õ½ºº´¿ø (¿Â¶óÀÎ)¼Ò¾Æû¼Ò³â°ú Çù·ÂÀÇ»ç Áý´ãȸ : 2024-05-28 0 21 2024-05-10
20663 ºÎ»ê ´ëÇѳ»°úÀÇ»çȸ Á¦1ȸ ÃÊÀ½ÆÄ ½ÇÀü ¾ÆÄ«µ¥¹Ì : 2024-05-27 0 20 2024-05-10
20662 ¼­¿ï ´ëÇѿ°èÁٱ⼼Æ÷Àç»ýÀÇÇÐȸ - Á¦20ȸ Ãá°èÇмú´ëȸ (ÇÏÀ̺긮µå) : 2024-05-26 0 14 2024-05-10
20661 ºÎ»ê ´ëÇÑ°áÇÙ ¹× È£Èí±âÇÐȸ ºÎ¿ï°æÁöȸ 5¿ù ¿¬¼ö°­Á : 2024-05-26 0 11 2024-05-10
20660 ¼­¿ï ´ëÇѽŰæ±Ù°ñ°áÃÊÀ½ÆÄÇÐȸ Á¦1ȸ ÇÚÁî¿Â ¿öÅ©¼ó : 2024-05-25 0 23 2024-05-10
20659 ´ëÀü ´ëÇÑÀ̺ñÀÎÈÄ°úÀÇ»çȸ 2024 Áöȸ½ÉÆ÷Áö¾ö-´ëÀüÃæ³² : 2024-05-25 0 8 2024-05-10
20658 ºÎ»ê ´ëÇÑÀÎÅͺ¥¼Ç¿µ»óÀÇÇÐȸ Á¦32Â÷ Á¤±âÇмú´ëȸ(2ÀÏÂ÷) : 2024-05-25 0 13 2024-05-10
20657 ´ë±¸ Ä¥°î°æºÏ´ëÇб³º´¿ø The 1st International Symposium on Precision Oncology in Breast Cancer : 2024-05-25 0 12 2024-05-10
20656 ¼­¿ï (¿Â¶óÀÎ)2024³â ´ëÇÑ°ñ´ë»çÇÐȸ Á¦1Â÷ FLS ÄÚµð³×ÀÌÅÍ ¿öÅ©¼ó : 2024-05-24 0 14 2024-05-10
20655 ¼­¿ï Á¦ 66ȸ Çѱ¹Ç×°ø¿ìÁÖÀÇÇÐȸ Ãá°èÇмú´ëȸ : 2024-05-24 0 7 2024-05-10
20654 ´ëÀü °ø°ø±â°ü ÀçÁ÷ÀÇ»ç Ãá°è Çмú´ëȸ (2ÀÏÂ÷) : 2024-05-24 0 9 2024-05-10
20653 ºÎ»ê ´ëÇÑÀÎÅͺ¥¼Ç¿µ»óÀÇÇÐȸ Á¦32Â÷ Á¤±âÇмú´ëȸ(1ÀÏÂ÷) : 2024-05-24 0 12 2024-05-10
20652 ¼­¿ï Çѱ¹Ç÷ÀüÁöÇ÷ÇÐȸ Á¦ 44 Â÷ KSTH Ãá°èÇмú´ëȸ : 2024-05-24 0 8 2024-05-10
20651 ¼­¿ï (¿Â¶óÀÎ)À̺ñÀÎÈÄ°ú Áö¿ªÀÇ»çÁý´ãȸ-°³¿ø°¡¿¡¼­ ÀÇ·ÚµÈ ÀÌ°ú Áúȯ : 2024-05-23 0 13 2024-05-10
20650 °æ±â Çϳ²½ÃÀÇ»çȸ¿¬¼ö°­ÁÂ(¸¸¼º±âħ, ºÒ¸éÁõ) : 2024-05-23 0 6 2024-05-10
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷